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Abstract
Amylo-α-1,6-glucosidase,4-α-glucanotransferase (AGL) is an enzyme primarily responsible for glycogen debranching. 
Germline mutations lead to glycogen storage disease type III (GSDIII). We recently found AGL to be a tumor suppressor 
in xenograft models of human bladder cancer (BC) and low levels of AGL expression in BC are associated with poor 
patient prognosis. However, the impact of low AGL expression on the susceptibility of normal bladder to carcinogenesis 
is unknown. We address this gap by developing a germline Agl knockout (Agl−/−) mouse that recapitulates biochemical 
and histological features of GSDIII. Agl−/− mice exposed to N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) had a higher 
BC incidence compared with wild-type mice (Agl+/+). To determine if the increased BC incidence observed was due to 
decreased Agl expression in the urothelium specifically, we developed a urothelium-specific conditional Agl knockout 
(Aglcko) mouse using a Uroplakin II-Cre allele. BBN-induced carcinogenesis experiments repeated in Aglcko mice revealed that 
Aglcko mice had a higher BC incidence than control (Aglfl/fl) mice. RNA sequencing revealed that tumors from Agl−/− mice had 
19 differentially expressed genes compared with control mice. An ‘Agl Loss’ gene signature was developed and found to 
successfully stratify normal and tumor samples in two BC patient datasets. These results support the role of AGL loss in 
promoting carcinogenesis and provide a rationale for evaluating Agl expression levels, or Agl Loss gene signature scores, in 
normal urothelium of populations at risk of BC development such as older male smokers.
Introduction
Bladder cancer (BC) is expected to occur in approximately 81 
000 patients in 2018, making it the fifth most common can-
cer in the USA (1). We have previously identified amylo-α-1,6-
glucosidase, 4-α-glucanotransferase (AGL) as a tumor suppressor 
in BC, with decreased AGL expression associated with increased 
tumor aggressiveness (2,3). AGL is a metabolic enzyme primarily 
responsible for glycogen debranching (4). Interestingly, we have 
shown that the canonical role of AGL, glycogen debranching, is 
Head1=Head2=Head1=Head2/Head1
Head2=Head3=Head2=Head3/Head2
not implicated in regulating tumor growth (2). Our investigations 
into the mechanisms underlying this noncanonical function 
have shown that increased growth and metastasis is related to 
increased expression of hyaluronic acid synthase 2  HAS2 sec-
ondary to AGL loss (3). Hyaluronic acid synthase 2 (HAS2) in turn 
leads to increased expression and secretion of hyaluronic acid 
that activates its receptors, CD44 and the hyaluronan-mediated 
motility receptor RHAMM and in this way promotes aggressive 
tumor behavior (5–7).
In addition to progressively lower AGL levels being associ-
ated with increased tumor aggressiveness, AGL expression is 
lower in tumors when compared with normal urothelium. These 
observations suggest that reduced AGL expression is permissive 
for bladder tumor formation. In humans, inactivating germline 
mutations of AGL have been observed and result in glycogen 
storage disease type III (GSDIII) (7–10). However, epidemiological 
studies examining whether GSDIII patients have a higher risk of 
developing BC are difficult because (i) the number of patients is 
small, (ii) most patients in international registries are relatively 
young and (iii) there is a low smoking prevalence. The latter two 
factors, age and tobacco use, are major risk factors for BC devel-
opment (8,11).
Given the inability to address this clinical question with epi-
demiological studies, we sought to develop novel murine mod-
els to address the gap in the literature regarding the role of AGL 
in malignant transformation of bladder urothelium. Herein, 
we describe a conventional germline Agl knockout mouse and 
use it to investigate N-butyl-N-(4-hydroxybutyl) nitrosamine 
(BBN)-induced bladder carcinogenesis. BBN is a common way to 
induce experimental BC and has been shown to mimic human 
disease development and molecular characteristics (12). To 
determine if the effects are due to lack of Agl specifically in the 
urothelium, we developed a conditional knockout model based 
on the Cre/LoxP system, in which Cre expression driven by the 
Uroplakin II (UpkII) promoter leads to the specific loss of Agl in 
the urothelium (13). Using these models, we show that Agl dele-
tion increases the incidence of BC, supporting its role as a sup-
pressor of transformation.
Materials and methods
Animal use and repository
All animal studies were performed in an AAALAC-approved facility with 
the approval of the University of Colorado–Denver Institutional Animal 
Care and Use Committee (IACUC). Animals are available to the scien-
tific community from the Gates Bioengineering Core at the University of 
Colorado–Denver.
Development of conventional germline Agl knockout 
(Agl−/−) mice
A conventional germline Agl knockout mouse strain was developed by 
injecting JM8A3.N1 ES cells containing a targeted Agl locus [Agltm1e(EUCOMM)Wtsi 
vector; European Conditional Mouse Mutagenesis (EUCOMM) program] 
into blastocysts, which were subsequently implanted in pseudopregnant 
females. Resulting founder mice were genotyped using primers developed 
by EUCOMM, with expansion of positive animals resulting in the establish-
ment of a targeted Agltm1e strain; hereafter referred to as Agl+/−. Although no 
exons were deleted in the tm1e allele, the allele is classified as a targeted, 
nonconditional knockout allele due to the preferential splicing that occurs 
with the En2-SA portion of the construct leading to a premature stop site 
incorporated after exon 5. A similar targeting strategy has been previously 
used to disrupt Agl (14). Heterozygous mice were intercrossed to produce 
Agl−/− mice. Agl+/+ mice were used as controls. Genotyping of 3-week old mice 
was performed from tail snips. DNA was isolated using the Qiagen DNAeasy 
Blood and Tissue kit (Valencia, CA). PCR was performed using GoTaq Green 
Master Mix (Promega, Madison, WI) with 0.4 µM PCR primers (Supplementary 
Table I). PCR products were visualized on 1% ethidium bromide agarose gels 
using a Bio-Rad ChemiDoc MP Imaging System (Hercules, CA). The wild-type 
Agl allele (Agl+/+) produces a PCR product of 522 bp whereas the Agl−/− allele 
produces a product of 395 bp. To verify systemic loss of AGL protein expres-
sion, a western blot of liver tissue was performed. Briefly, liver was homog-
enized in RIPA lysis buffer and quantified by BCA kit (Thermo Scientific, 
Rockford, IL). Samples were run on a 4–20% Tris-glycine gel (Thermo 
Scientific), transferred to polyvinylidene difluoride, blocked in 5% nonfat dry 
milk and probed with rabbit polyclonal anti-AGL (Agrisera, Vännäs, Sweden) 
and mouse monoclonal anti-tubulin (Developmental Studies Hybridoma 
Bank, University of Iowa, Iowa City, IA) overnight. Blots were imaged using a 
Bio-Rad ChemiDoc MP Imaging System.
Development of urothelium-specific Agl conditional 
knockout (Aglcko) mice
Derivation of an urothelium-specific conditional knockout mouse strain 
(Aglcko) was achieved through in vitro fertilization using sperm (B6NTac;B6N-
Agltm1a(EUCOMM)Wtsi) from EUCOMM and wild-type C57BL/6J oocytes. Fertilized 
ova were transferred at the two-cell stage into pseudopregnant female recipi-
ents as described previously (15). Resulting Agltm1a mice were then mated with 
mice from the FLPo deleter strain 129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J 
(The Jackson Laboratory, Bar Harbor, ME) to remove the FRT sites on either 
side of the neomycin selection and lacZ cassettes, leaving only loxP sites 
flanking exons 6–10. These mice (Agltm1c, subsequently referred to as Aglfl/+) 
were intercrossed to create Aglfl/fl mice. Aglfl/fl mice were then bred with 
Uroplakin II-Cre mice (UpkII-Cre+/Tg; a generous gift from Dr. Xue-Ru Wu) (16), 
in which Cre expression is restricted to the bladder urothelium (16–18). The 
resulting Aglfl/+;UpkII-Cre+/Tg mice were then crossed with Aglfl/fl mice to prod-
uce Aglfl/fl;UpkII-Cre+/Tg mice, subsequently referred to Aglcko mice. Aglfl/fl mice 
were used as controls for all experiments. Genotyping was performed as 
described earlier. PCR primers are described in Supplementary Table I. The 
presence of Cre is identified through a 420 bp product. The wild-type Agl 
allele produces a 522 bp PCR product whereas the Aglfl/fl allele produces a 
719 bp product. Under non-recombined conditions, the distance between 
the primers to assess recombination is 10.6 kb, a band size not probably 
seen in most PCRs. Cre-based recombination of the Aglfl/fl allele produces an 
829 bp product using the described recombination primers.
BBN carcinogenesis in genetically engineered mice
Mice were treated with 0.05% or 0.1% BBN (TCI America, Portland, OR) 
in drinking water per schedules shown in Figures  1 and 2. Bottles were 
refreshed with BBN twice weekly and mice were allowed to drink ad libitum. 
Mice were inspected weekly for any endpoint that would trigger euthan-
asia according to our IACUC-approved protocol. After 12 weeks, BBN was 
removed from the water. Mice were euthanized at the time points shown 
in Figures 1 and 2. Bladder, liver, skeletal muscle (rectus femoris and vastus 
medialis) and heart were harvested, bisected and fixed in 4% paraformal-
dehyde (Affymetrix, Cleveland, OH) or snap frozen in liquid nitrogen.
Glycogen biology assays
Glycogen debranching enzyme (GDE) activity was measured as described 
elsewhere (9,19,20). Skeletal muscle, heart and liver tissue were isolated, 
and analysis performed by an indirect assay based on stimulation of 
the incorporation of radioactive glucose into glycogen. The reaction was 
stopped after 5 and 10 min and the enzyme activity was measured. We 
evaluated GDE activity as the average of the two determinations. Enzyme 
Abbreviations 
AGL   amylo-α-1,6-glucosidase,4-α-
glucanotransferase
BBN N-butyl-N-(4-hydroxybutyl) nitrosamine
BC bladder cancer
GDE glycogen debranching enzyme
GDF15 Growth differentiation factor 15
GSDIII glycogen storage disease type III
ITGB4 integrin subunit beta 4
qPCR quantitative real-time PCR
RNA-seq RNA sequencing
UPKII Uroplakin II
activity was expressed as picomoles of glucose incorporated into glyco-
gen/min/mg protein. Amyloglucosidase digestion of ethanol-precipitated 
glycogen was used to assess tissue glycogen content. Glucose concentra-
tion was estimated after amyloglucosidase digestion with Glucose (HK) 
Assay Kit (Sigma–Aldrich, St. Louis, MO). Absorbance was read at 340 nm 
after a 15 min incubation at room temperature (9,19).
Tumor histology
Paraformaldehyde-fixed tissues were paraffin-embedded and processed 
for hematoxylin and eosin staining to assess size and organization of 
tumors. All bladders were evaluated by a board-certified pathologist in a 
blinded manner with respect to the mouse genotype. Histologic images 
were acquired using an Olympus DP27 camera (Olympus, Parkway Center 
Valley, PA) and Leica Aperio ImageScope software (Wetzlar, Germany).
RNA sequencing
Flash-frozen tumor samples from Agl+/+ and Agl−/− mice were weighed, 
crushed, and RNA purified using the RNeasy Plus Mini Kit (Qiagen). RNA 
was subsequently sent to Novogene (Chula Vista, CA), where library prep-
aration and RNA sequencing (RNA-seq) were performed). Differentially 
expressed genes were determined using Novogene’s standard analysis 
pipeline, which includes aligning reads using TopHat2 and differen-
tial expression analysis using DESeq2  ‘R’ package with an false discov-
ery rate  (FDR) <0.05. All relevant files were uploaded to the NCBI Gene 
Expression Omnibus repository (GSE113158).
Microarray analysis
For microarray analysis, gene expression datasets from two BC patient 
cohorts were used. The Memorial Sloan Kettering Cancer Center cohort 
consists of 129 samples reported by Sanchez-Carbayo et  al. (21). The sec-
ond cohort consists of 175 samples collected from the Chungbuk National 
University Hospital (22), with Gene Expression Omnibus accession number 
GSE13507 (23). For genes with multiple probes, the probe with the highest 
mean expression was used (24). For each probe, expression values were nor-
malized to have a mean expression of 0 and standard deviation of 1. The 
‘Agl Loss’ score is the sum of normalized expression values of genes whose 
expression are higher in tumors of Agl−/− mice minus the sum of normal-
ized expression values for genes that are lower in Agl−/− tumors compared 
with Agl+/+ tumors. Thus, human tumors with higher scores are more like 
Agl−/− tumors than those human tumors with lower scores. The area under 
the receiver operating characteristics curve, fold changes and nonparametric 
Wilcoxon rank sum test were used to evaluate whether gene expression val-
ues for single genes or Agl−/− scores differed between BC and normal human 
urothelium samples. P-values of <0.05 are considered statistically significant.
Quantitative real-time PCR
RNA was prepared from flash-frozen tumor as described earlier for 
RNA-seq analysis and reverse transcribed using the iScript Reverse 
Transcription Supermix (Bio-Rad). Quantitative real-time PCR (qPCR) was 
performed in duplicate for each tumor using iTaq Universal SYBR Green 
Supermix (Bio-Rad) in a 10 µl reaction volume on a QuantStudio 6 Flex 
Figure 1. Incidence of BC in Agl−/− mice. (A) Overview of experimental design and two cohorts. Both cohorts were treated with 0.05% BBN for 12 weeks prior to euthan-
asia at 8 (cohort 1) or 16 (cohort 2) weeks after discontinuing BBN. (B) Representative hematoxylin and eosin images of tumor bearing bladders from Agl+/+ and Agl−/− mice 
are shown. (C) Agl−/− mice from cohort 1 had an increased, though not statistically significant, tumor incidence compared with Agl+/+ mice (P > 0.05). (D) Agl−/− mice in 
cohort 2 had an increased, though not statistically significant, tumor incidence compared with Agl+/+ mice (P > 0.05). Fisher’s exact test was used for statistical analysis.
(Applied Biosystems, Foster City, CA). Measurements from duplicate Ct 
values were normalized to Fkbp5, averaged and reported using the ΔΔCt 
method.
Statistical analysis
Statistical analyses, not previously detailed, were performed using 
GraphPad Prism v7 software (GraphPad Software, La Jolla, CA). Student’s 
t-test and Fisher’s exact tests were used to analyze carcinogenesis data.
qPCR data were analyzed using ROUT to identify and remove statistical
outliers followed by the Kolmogorov–Smirnov test. Power calculations,
comparing two independent samples with inference for proportions with 
α = 0.05, power = 0.8, two-sided test, were performed using the online cal-
culator available at https://www.stat.ubc.ca/~rollin/stats/ssize/b2.html. 
Results are means ± SEM, and significance is represented by *P  <  0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001
Results
Development of a germline Agl knockout (Agl−/−) 
mouse model
We have shown previously that inhibition of AGL leads to 
enhanced tumor growth (2). However, the impact AGL loss has 
on the incidence of urothelial carcinogenesis has yet to be deter-
mined. Therefore, a germline (full body) Agl knockout mouse 
(Agl−/−) strain was developed and used to determine if AGL loss 
changes the incidence of BC following carcinogen exposure. AGL 
loss was evaluated using PCR (Supplementary Figure  1A) and 
western blotting (Supplementary Figure 1B). Although we were 
developing our Agl−/− mice, two other groups reported genetically 
similar animals (9,14). Our model system uses a similar construct 
as described in Liu et al. (14), but was derived independently. We 
observed that our Agl−/− mice were fertile but produced small lit-
ters (1–2 pups), thus making large-scale experiments quite chal-
lenging. Importantly, we did not see any no histological evidence 
of altered bladder development or structural abnormalities in 
the Agl−/− mice we derived (Supplementary Figure 1C).
Impact of germline loss of Agl on BBN induction of 
bladder cancer in mice
To investigate the impact of germline Agl disruption on BC inci-
dence, Agl−/− and Agl+/+ mice were treated with 0.05% BBN for 12 
weeks. BBN-treated mice were then divided into two cohorts 
(Figure 1A). The first group of mice (cohort 1; Agl−/−, n  =  8 and 
Figure 2. Incidence of BC in mice with urothelium-specific loss of Agl. (A) Diagram of the Agl targeting construct used to generate a urothelium-targeted allele for 
Agl knockout. FLPo-mediated excision followed by Cre recombinase-mediated recombination (by crossing with UpkII-Cre mice) leads to targeted deletion of Agl in the 
urothelium. Relative primer locations and amplicon sizes expected from genotyping are shown. (B) The breeding strategy used to develop control (Aglfl/fl) and Aglcko 
(Aglfl/fl;UpkII-Cre+/Tg) mice. (C) PCR genotyping of animals; the floxed Agl allele produces a 719 bp amplicon whereas the wild-type Agl allele produces a 522 bp amplicon. 
The presence of Cre produces a 420 bp amplicon. Cre-based Agl recombination was confirmed in the bladders of Aglcko mice by an 829 bp recombination-specific ampli-
con. (D) Mice were treated with 0.05% BBN for 12 weeks and euthanized 4 weeks following BBN discontinuation. (E) Aglcko mice had an increased, though not statistic-
ally significant (P > 0.05), incidence of tumor formation compared with Aglfl/fl mice. (F) Representative histologic analyses of Aglfl/fl and Aglcko mice with normal bladder 
epithelium and invasive carcinomas are shown. Fisher’s exact test was used for statistical analysis.
Agl+/+, n = 10) were euthanized 8 weeks after discontinuation of 
BBN treatment. The second group of mice (cohort 2; Agl−/−, n = 7 
and Agl+/+, n = 11) were euthanized 16 weeks after discontinu-
ation of BBN treatment. Bladders from all mice were isolated 
and histologic analysis was performed (Figure 1B). We observed 
that Agl−/− mice in both cohorts had an increased, though non-
statistically significant tumor incidence compared with Agl+/+ 
mice (Figure 1C and D). Because of the small litter sizes, a power 
calculation was performed and determined that 134 mice per 
group would be necessary to fully assess significant differences 
between these groups. The observations concerning increased 
tumor incidence in Agl−/− mice support our previous observation 
implicating AGL as a tumor suppressor.
Agl−/− mice created by other groups showed signs of glyco-
gen storage disease similar to human GSDIII (9,14). We sought to 
determine if the mice we developed, and treated with 0.1% BBN, 
harbored similar pathologies. We found that the livers of Agl−/− 
mice treated with BBN were significantly enlarged compared 
with livers of Agl−/− mice (P  <  0.05; Supplementary Figure  1D). 
Hematoxylin and eosin stained sections of liver, heart and skel-
etal muscle tissue from Agl−/− mice showed tissue architecture 
associated with the accumulation of glycogen in hepatocytes 
compared with Agl+/+ mice (Supplementary Figure 2) similar to 
previous observations (9,14). These pathologies were like those 
described previously in other models of GSDIII (9,14,19). In add-
ition, we measured GDE, the enzyme encoded by the Agl gene, 
activity in liver, heart and skeletal muscle. In these tissues, 
GDE activity was significantly decreased in Agl−/− mice when 
compared with Agl+/+ mice (P < 0.05); Supplementary Figure 1E). 
Furthermore, glycogen content in all tissues examined was 
significantly increased (P  <  0.05), due to decreased ability to 
debranch and mobilize glycogen (Supplementary Figure  1F). 
The GSDIII phenotype observed in our Agl−/− BBN-treated mice is 
retained similarly to previously published accounts in non-BBN-
treated mice (9,14).
Impact of urothelium-specific loss of AGL on BBN 
induction of BC in mice
Germline deletion of Agl may lead to systemic metabolic altera-
tions such as GSDIII. Such germline deletion may also impact 
BC development by altering BBN metabolism that occurs in the 
liver (25,26), possibly altering the carcinogenic potential of BBN. 
To mitigate these concerns, we developed a model of Agl loss 
specific to the bladder urothelium. Briefly, mice carrying a floxed 
Agl allele (Aglfl/fl) (Figure 2A and B) were crossed with mice car-
rying a UpkII promoter-driving Cre expression (UpkII-Cre) (13). 
UpkII expression has been shown previously to be restricted to 
the bladder urothelium (27,28), meaning that Aglfl/fl;UpkII-Cre+/Tg 
(Aglcko) mice have a urothelium-specific loss of Agl. To confirm 
Agl recombination and functional deletion of Agl, a confirma-
tory analysis was performed on the bladders of a cohort of mice. 
Indeed, the presence of an 829 bp amplicon confirms the Cre-
based recombination of Agl specific to the bladder (Figure 2C). 
PCR validation was necessary due to the lack of an adequate 
antibody for immunohistochemistry despite our best efforts 
to perfect this technique (data not shown). To investigate the 
impact of urothelium-specific loss of Agl on BC incidence, mice 
(Aglfl/fl, n = 17 and Aglcko, n = 18) were treated with 0.05% BBN for 
12 weeks and then euthanized 4 weeks after discontinuing BBN 
treatment (Figure 2D). A power calculation determined that 200 
mice per group would be necessary to fully assess significant 
differences between these groups. Histologic analysis of blad-
der tissue showed an increased, though not statistically signifi-
cant, tumor incidence in Aglcko mice when compared with Aglfl/
fl mice (Figure 2E). A wide variety of tumor sizes were observed 
in both groups, with some tumors only measureable microscop-
ically whereas others were observed to be large and invasive 
(Figure  2F). As for the germline deletion mouse, these obser-
vations further support our previous observation that AGL is a 
tumor suppressor.
RNA sequencing analysis of bladder tumors from 
wild-type and germline Agl-deleted mice
To begin our understanding of the mechanism by which Agl 
loss leads to a greater susceptibility to BBN-induced BC, tumors 
were isolated from Agl+/+ and Agl−/− mice (n = 4 per group) and 
prepared for RNA-seq. Tumors from Agl+/+ and Agl−/− mice were 
used because of the cleaner biological system afforded by the 
germline Agl deletion compared with tumors from Aglcko mice. 
In Aglcko mice, Agl expression from the tumor-associated stroma 
and immune infiltrate would potentially confound the results 
as Agl would be expressed from all cells outside the urothelium. 
Furthermore, because GSDIII is rare, our Agl−/− mouse model is 
perhaps the most practical approach to study tumor predispos-
ition in these patients as discussed earlier.
Unsupervised hierarchical clustering of the eight tumor 
samples significantly differentiated Agl+/+ and Agl−/− tumor sam-
ples (Figure 3A), with six genes significantly downregulated and 
13 genes significantly upregulated (FDR < 0.05) in Agl−/− mice 
(Figure 3B; Supplementary Table II). Agl was identified as one of 
the genes significantly (P < 0.05) downregulated in Agl−/− tumors, 
and was validated by qPCR (Supplementary Figure  3), further 
validating the knockout model. To determine the global bio-
logical relevance of these genes, we developed an Agl Loss gene 
signature score. We sought to determine if normal urothelial 
samples and tumor tissue from patients with BC had different 
Agl Loss scores. Using data from two publicly available patient 
datasets, where both tumor tissue and normal tissue were avail-
able (CNUH and MSKCC (21,22)), we found that the ‘Agl Loss’ 
score was significantly (P < 0.05) higher in tumor than normal 
tissue (Figure 3C), supporting the notion that AGL loss plays a 
role in BC formation. Single gene analysis of the 19 genes iden-
tified by RNA-seq was then performed to identify genes with 
significant relationships and directionalities to those identi-
fied in the Agl−/− mice. Interestingly, we identified ITGB4 (integ-
rin subunit beta 4) and GDF15 (growth differentiation factor 15). 
We validated increased expression of Itgb4 and Gdf15 by qPCR in 
Agl+/+ and Agl−/− tumors (n = 8 per group; Figure 3D). Furthermore, 
we investigated if genes described previously to be associated 
with AGL (3) could be validated in our Agl−/− mice. Even though 
we observed gene expression changes matching the direction of 
previous observations (e.g. increased hyaluronic acid synthase 
2  (HAS2) expression in AGL Agl−/− mice), the results were not 
statistically significant (P > 0.05). Both genes show significantly 
higher expression in patient tumor tissue compared with nor-
mal urothelium matching the observations made in the mice 
(Figure 3E and F). These data provide evidence that the obser-
vations in our mouse models have translational relevance to 
human disease.
Discussion
We and others have shown AGL is a suppressor of tumor growth 
in established tumor models (2,3,6). Herein, we sought to deter-
mine if AGL expression in normal tissues impacts their sus-
ceptibility to carcinogenesis. To investigate this question, we 
developed conventional germline and conditional bladder-spe-
cific AGL knockout murine models. Our germline Agl−/− knockout 
model recapitulates previous findings of a murine GSDIII pheno-
type, confirming the validity of our model (14). Even though the 
observed increase in tumor incidence in our Agl KO models was 
not statistically significant, our data suggest that AGL has a role 
in bladder carcinogenesis, especially because the same result 
was obtained with mice having conditional knockout of Agl in 
bladder urothelium. However, the relative importance of AGL 
loss in driving carcinogenesis, and how this compares with AGL 
loss in driving established tumors, remains unclear (2,3).
Our work defined a novel ‘Agl Loss’ gene signature com-
posed of the 19 differentially expressed genes from RNA-seq of 
tumors resulting from BBN carcinogenesis. The Agl Loss score 
was able to stratify normal and BC tissue from publicly avail-
able datasets (21,22). These findings support the biological and 
clinical relevance of murine tumors derived from normal tis-
sues lacking AGL. Interestingly, the 19 genes identified herein 
were not differentially expressed in our previously described 
model of shAGL (3). In the previously referenced experiments, 
established human BC cells were transduced with a shAGL 
construct to reduce AGL protein levels (3). The lack of simi-
larity between the referenced shAGL experiments and those 
presented herein are not surprising for several reasons. The 
species used in the two studies were different. In the currently 
described murine experiments, normal urothelium-lacking 
AGL was transformed by chemical carcinogens. It is plausible 
that incomplete protein knockdown by shAGL lead to a dif-
ferent transcriptional profile than conventional germline Agl 
knockout in the mouse models described previously. We can 
also speculate that AGL loss prior to transformation can result 
in a different transcriptional program than AGL loss occurring 
during tumor progression. Despite the biological and technical 
differences between microarray and RNA-seq, evaluation of 
the top five genes identified in Guin et al. (3) revealed similar 
albeit nonstatistically significant relationships when compar-
ing tumors with and without AGL expression. To begin to deter-
mine the reason for these differences, it would be of interest to 
develop BC cell lines from murine tumors of Agl+/+, Agl−/−, Aglfl/
fl and Aglfl/fl;UpkII-Cre+/Tg mice and transcriptionally profile them 
after knockout of Agl or reconstitution with a constitutively 
active Agl, as appropriate.
One of the 13 genes with increased expression in Agl−/− 
tumors was Gdf15. We found expression of GDF15 is increased 
in human BC compared with normal tissue. GDF15 is a member 
of the transforming growth factor-beta  (TGF-beta) superfamily 
first described as an inhibitor of macrophages (29). Interestingly, 
GDF15 is typically expressed at low levels in a majority of normal 
tissues but has high expression in liver (29). Coincidently, the 
primary organ impacted by the loss of AGL is liver (30). GDF15 
upregulation in the context of BBN carcinogenesis is compatible 
with the inevitable inflammation caused by carcinogenic stimuli 
(31). Increased GDF15 expression has been associated with older 
age, male sex, smoking and obesity; all of which are known risk 
factors for BC (32). Although the full role of GDF15 remains to be 
determined, studies indicate GDF15 may have both tumor sup-
pressor (33,34) and pro-tumorigenic (35,36) functions. This is not 
dissimilar to characteristics of other members of the transform-
ing growth factor-beta superfamily, where their role is context 
dependent (37,38). Interestingly, GDF15 has been identified as a 
BC biomarker (39), with increased levels being associated with 
poor outcome (40).
Our transcriptomic analysis of Agl−/− tumors also identified 
Itgb4 as being upregulated in Agl−/− tumors. Integrins are deeply 
implicated in tumor biology, and have been shown to play crit-
ical roles in metastasis and microenvironmental interactions 
(41). Increased ITGB4 has previously been associated with more 
aggressive BC and hepatocellular carcinoma phenotypes (42,43). 
Figure 3. RNA-seq analysis of bladder tumors derived from Agl−/− and Agl+/+ mice identifies a tumor-promoting gene set. RNA-seq was performed on Agl+/+ (n = 4) and 
Agl−/− (n = 4) mice. (A) Unsupervised clustering of the eight tumors properly segregates tumors from Agl+/+ and Agl−/− mice. (B) Volcano plot depicting the 19 significant 
(P-adj < 0.05) differentially expressed genes in Agl−/− mice compared with Agl+/+ mice. (C) The ‘Agl Loss’ score was defined from the 19 differentially expressed genes 
identified and used to determine if it could appropriately discriminate normal bladder urothelium and tumor tissue from patients from two independent and publicly 
available datasets. Two differentially expressed genes in the human dataset, (D) Itgb4 and Gdf15 were validated in Agl−/− and Agl+/+ mouse tumors by qPCR. Additionally, 
(E) ITGB4 and (F) GDF15 have significantly higher levels in tumor tissue compared with normal tissue. Bars denote significant differences (P < 0.05).
Increased tumor aggressiveness due to ITGB4 expression is 
associated with an induction of epithelial–mesenchymal tran-
sition, primarily through an upregulation of Slug (43). Our prior 
work has implicated the pro-tumorigenic properties of CD44, 
so it was interesting to observe other cell adhesion molecules, 
such as ITGB4, playing a role in mediating the aggressive pheno-
type conferred by AGL loss (5,6,44). Taken together, these obser-
vations suggest that AGL may be functioning through a shared 
pathway that leads to loss of contact inhibition and increased 
tumor growth. These alterations may also lead to increased 
metastasis because loss of cell adhesion molecules is a hallmark 
of the metastatic cascade (45,46).
The tumor microenvironment is well known to regulate 
tumor growth and impact tumor heterogeneity (31,47,48). 
Therefore, the development of a bladder urothelium-specific 
knockout of Agl is important for future studies as a BC model 
with clinical relevance. The conditional knockout model 
addresses a weakness of Agl−/− models, in that the gene of inter-
est is only altered in the tissue of interest rather than the entire 
organism. For example, in the Agl−/− model, Agl is lost in hepato-
cytes, macrophages, neurons, endothelial cells and all other 
cells, which may impact aspects of carcinogenesis our model 
did not detect. However, the Agl−/− strain is useful to study can-
cer predisposition in patients with GSDIII. Indeed, our work sug-
gests that GSDIII patients may have an increased susceptibility 
to BC development, and further investigation is necessary to 
determine if GSDIII patients should undergo increased screen-
ing for development of BC.
Finally, the concept of field cancerization, where widespread 
carcinogenic alterations occur in a large proportion of cells 
despite a lack of morphologic differentiation, is understood 
to contribute to the multifocal nature of BC development (49). 
Our findings support studies aimed at evaluating individuals 
at higher risk for BC (e.g. smokers) for reduced AGL expression 
in their urothelium. If smokers have decreased AGL expression 
compared with nonsmokers, these data would be supportive of 
the role AGL plays in BC carcinogenesis. Further, as not all smok-
ers develop BC, individuals that smoke and have decreased AGL 
expression may be at an even higher risk for developing BC, and 
thus may be candidates for screening (50).
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